AstraZeneca defends Crestor
This article was originally published in The Tan Sheet
Executive Summary
A Circulation article linking Crestor (rosuvastatin) to a higher risk of muscle and kidney toxicity compared to other statins is misleading and in "direct contrast" to FDA's position, AstraZeneca says May 23. The study by Alawai Alsheikh-Ali, Tufts-New England Medical Center, et al., "attempts to draw conclusions that simply cannot be drawn from adverse event reporting data," the firm says. The findings were released in May (1"The Tan Sheet" May 30, 2005, p. 6)...
You may also be interested in...
Circulation Articles Question Crestor, Stress Statin Selection Complexity
Appropriate selection of cholesterol-lowering statins is complicated by determining desirable LDL levels for a patient and comparing side-effect profiles of drugs in the class, an editorial in the May 23 issue of Circulation maintains
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.